In our study, 90% of patients with CLL had positive CD160 expression on B-cell clones by percentage versus 60% B-NHL and 60% HCL, while by MFIR 96.7% of patients with CLL had positive CD160 B-cell clones versus 80% B-NHL and 60% HCL. Here, CD160 is linked to non-Hodgkin lymphoma.